Literature DB >> 20660535

Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.

Nancy J Brown1.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis and regulates cell migration and fibrosis. Preclinical studies using genetically altered mice and biological or small molecule inhibitors have elucidated a role for PAI-1 in the pathogenesis of thrombosis, vascular remodeling, renal injury, and initiation of diabetes. Inhibition of PAI-1 is a potential therapeutic strategy in these diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660535     DOI： 10.1177/1753944710379126

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN： 1753-9447


  16 in total

1.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

3.  A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.

Authors:  Jiandong Zhang; Chunyan Gu; Daniel A Lawrence; Alfred K Cheung; Yufeng Huang
Journal:  Exp Physiol       Date:  2014-01-17       Impact factor: 2.969

4.  Redox control of p53 in the transcriptional regulation of TGF-β1 target genes through SMAD cooperativity.

Authors:  Jessica M Overstreet; Rohan Samarakoon; Kirstan K Meldrum; Paul J Higgins
Journal:  Cell Signal       Date:  2014-03-05       Impact factor: 4.315

5.  Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers.

Authors:  Jared Damare; Stephanie Brandal; Yolanda M Fortenberry
Journal:  Nucleic Acid Ther       Date:  2014-06-12       Impact factor: 5.486

6.  Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.

Authors:  G H Tofler; J Massaro; C J O'Donnell; P W F Wilson; R S Vasan; P A Sutherland; J B Meigs; D Levy; R B D'Agostino
Journal:  Thromb Res       Date:  2016-02-03       Impact factor: 3.944

Review 7.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Authors:  Veronica R Placencio; Yves A DeClerck
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

8.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

9.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

Review 10.  Cell senescence and fibrotic lung diseases.

Authors:  Rui-Ming Liu; Gang Liu
Journal:  Exp Gerontol       Date:  2020-01-17       Impact factor: 4.032
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.